New nausea drug could replace old standby in ERs
NCT ID NCT06740812
First seen Oct 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This study will compare two nausea medications—fosaprepitant and metoclopramide—in 212 adults coming to the emergency department with nausea or vomiting. Half will get fosaprepitant, half metoclopramide, and neither they nor their doctors will know which. The goal is to see which provides faster, more lasting relief with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAUSEA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fosaprepitant and metoclopramide
What this could lead to
If fosaprepitant works better than metoclopramide, it could offer a new, affordable option for nausea relief in emergency rooms.
What could go wrong
This is a single-site trial with only 212 participants, so results may not apply broadly. Both drugs have known side effects, and the study hasn't started yet.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.